The FDA is trying something new to solve an old problem: America doesn't make enough of its own medicine anymore. On Sunday, the agency opened applications for PreCheck, a pilot program that promises to make building pharmaceutical plants in the U.S. less of a regulatory headache.
The pitch is straightforward. If you're willing to manufacture drugs domestically, the FDA will work with you early in the process to iron out regulatory issues before you submit a formal drug application. That means fewer surprises, faster approvals, and more certainty that your multibillion-dollar investment won't get stuck in approval limbo.
FDA Commissioner Marty Makary framed the initiative as part of a broader push to reverse decades of offshoring and rebuild America's pharmaceutical manufacturing capacity. The goal isn't subtle: make the U.S. competitive again as a place to actually produce drugs, not just develop them.
How PreCheck Actually Works
The FDA plans to select its first batch of facilities in 2026, focusing on plants that check certain boxes. They're looking for alignment with national priorities, which includes the types of products being made, how far along the facility is in development, how quickly it can start supplying the U.S. market, and whether it uses cutting-edge manufacturing techniques. Facilities producing critical medicines get extra points.
PreCheck unfolds in two stages. The Facility Readiness Phase kicks things off with early technical guidance through pre-operational reviews and a facility-specific Drug Master File. This lets the FDA evaluate your manufacturing setup before you even submit a drug application. Then comes the Application Submission Phase, which builds on that groundwork with pre-submission meetings and inspections designed to catch problems early and speed up the review of manufacturing data.
The whole structure is meant to reduce supply-chain risk while creating real financial incentives for companies to invest in American manufacturing capacity instead of going overseas.
Lilly Puts Billions Behind U.S. Manufacturing
The timing is notable. On Friday, Eli Lilly and Co. (LLY) announced plans to invest more than $3.5 billion in a new manufacturing facility in Pennsylvania's Lehigh Valley. The site will produce injectable medicines and devices, including retatrutide, an experimental triple-hormone weight-loss therapy that targets GIP, GLP-1, and glucagon receptors simultaneously.
This marks Lilly's fourth new U.S. manufacturing site announced since February 2025, reflecting the company's broader commitment to domestic production. The Pennsylvania facility will create 850 permanent jobs and an estimated 2,000 construction jobs when building starts in 2026. The plant is expected to become operational in 2031.
LLY Price Action: Eli Lilly shares were up 1.70% at $1,054.73 at the time of publication on Monday.
